A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NCT06680830)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension to Evaluate the Safety and Efficacy of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
Who can join: Review the eligibility criteria below.
Location: Banner Sun Health Research Institute — Sun City, Arizona
Age range: 40 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (72 Sites)
Showing the first 25 of 72 sites.
- Banner Sun Health Research Institute — Sun City, Arizona
- University of Arkansas — Little Rock, Arkansas
- Neuro-Pain Medical Center — Fresno, California
- University of California, Irvine — Irvine, California
- University of California, Los Angeles — Los Angeles, California
- Esperanza Clinical — Murrieta, California
- Parkinson's Research Centers of America - Palo Alto — Palo Alto, California
- Sutter Neuroscience Institute — Sacramento, California
- University of Colorado - Anschutz Medical Campus — Aurora, Colorado
- Parkinson's Disease and Movement Disorders Center of Boca Raton — Boca Raton, Florida
- University of Florida — Gainesville, Florida
- Neurology One — Orlando, Florida
- USF Parkinson's & Movement Disorders Clinic — Tampa, Florida
- Emory University — Atlanta, Georgia
- Augusta University — Augusta, Georgia
- Northwestern Medical Group, Department of Neurology — Chicago, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- University of Kentucky — Lexington, Kentucky
- Ochsner Clinic Foundation — New Orleans, Louisiana
- University of Maryland — Baltimore, Maryland
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Quest Research Institute — Farmington Hills, Michigan
- Struthers Parkinson Center — Golden Valley, Minnesota
- Cleveland Clinic — Las Vegas, Nevada
- University of New Mexico — Albuquerque, New Mexico
📞 Contact the Study Coordinator
Phone: (650) 228-2527
Email: clinicaltrials@neuron23.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson Disease
- Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation — Tucson, Arizona
- Parkinson's Disease Progression Study — Aurora, Colorado
- To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Birmingham, Alabama
- Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) — Seattle, Washington
- Automated Imaging Differentiation of Parkinsonism — Birmingham, Alabama
- Study in Parkinson Disease of Exercise — Birmingham, Alabama
Explore by condition: All Parkinson Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.